Research Topics
Genomes and Genes
| Christopher L CorlessSummaryAffiliation: Oregon Health and Science University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profilesSubbaya Subramanian
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
Oncogene 23:7780-90. 2004..These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated...- Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfallMaggie M Lam
Department of Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
Int J Gynecol Pathol 25:288-92. 2006..Thus, it is imperative to consider EGISTs in the differential diagnosis of mesenchymal neoplasms in the vulvovaginal/rectovaginal septum... 
Tackling formalin-fixed, paraffin-embedded tumor tissue with next-generation sequencingChristopher L Corless
Department of Pathology, and Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA
Cancer Discov 2:23-4. 2012..A new study by Wagle and colleagues shows that a combination of hybridization-capture and deep sequencing yields high-quality data from FFPE specimens...
Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemiaChristopher L Corless
OHSU Dept of Pathology L471, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
J Mol Diagn 8:604-12. 2006..Thus, the assay may be useful in confirming the diagnosis of SM...- Molecular pathobiology of gastrointestinal stromal sarcomasChristopher L Corless
Department of Pathology, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
Annu Rev Pathol 3:557-86. 2008.... - KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumorsChristopher L Corless
Department of Pathology, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
J Mol Diagn 6:366-70. 2004..Laboratories that offer clinical screening for KIT mutations in GI stromal tumors should be aware of this class of mutations... - PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinibChristopher L Corless
Department of Pathology, Division of Hematology and Oncology, Oregon Health and Science University Cancer Institute, Portland, OR 97201, USA
J Clin Oncol 23:5357-64. 2005..Little is known of the other types of PDGFRA mutations that occur in GISTs... - Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorMichael C Heinrich
Division of Hematology Oncology, Department of Medicine and Cell and Developmental Biology, Portland Veterans Affairs Medical Center and Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
J Clin Oncol 26:5352-9. 2008..We evaluated the impact of primary and secondary kinase genotype on sunitinib activity... - The gene expression profile of extraskeletal myxoid chondrosarcomaSubbaya Subramanian
Department of Pathology, Stanford University Medical Center, Stanford, CA 94035, USA
J Pathol 206:433-44. 2005..Small molecule inhibitors for PPARG exist and PPARG could be a potential therapeutic target for EMC... - Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KITCharles D Blanke
Oregon Health and Science University Cancer Center and Portland Veterans Affairs Hospital, Portland, OR, USA
J Clin Oncol 26:620-5. 2008..We conducted a long-term analysis of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status... - Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich
R and D 19 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
J Clin Oncol 21:4342-9. 2003..The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST... - Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs)Anette Duensing
Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Cancer Res 64:5127-31. 2004..PKCtheta is strongly activated in most GISTs and hence may serve, along with KIT/PDGFRA, as a novel therapeutic target... - Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypesBernadette Liegl
Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Am J Surg Pathol 33:437-46. 2009..DOG1.1 is also a sensitive marker for unusual GIST subgroups lacking KIT or PDGFRA mutations. In tumors that are negative for both KIT and DOG1.1, mutational screening may be required to confirm the diagnosis of GIST... - Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesisGangwen Han
Department of Otolaryngology, Oregon Health and Science University, Portland, OR, USA
J Clin Invest 115:1714-23. 2005..TGF-beta1-mediated EMT requires functional TGF-(beta)RII, whereas TGF-beta1-mediated tumor invasion cooperates with reduced TGF-(beta)RII signaling in tumor epithelia... - High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breastMegan L Troxell
Department of Pathology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
Mod Pathol 23:27-37. 2010..These findings indicate that approximately two-thirds of papillomas are driven by mutations in the PI3CA/AKT pathway. Some papillary carcinomas may arise from these lesions, but others may have different molecular origins... - Molecular correlates of imatinib resistance in gastrointestinal stromal tumorsMichael C Heinrich
Division of Hematology Oncology, Department of Pathology, Oregon Health and Science University Cancer Institute, Oregon Health and Science University, Portland, OR, USA
J Clin Oncol 24:4764-74. 2006..In clinical studies, 75% to 90% of patients with advanced GISTs experience clinical benefit from imatinib. However, imatinib resistance is an increasing clinical problem... - KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implicationsFabiola Medeiros
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
Am J Surg Pathol 28:889-94. 2004..Notably, some KIT-negative GISTs contain imatinib-sensitive KIT or PDGFRA mutations; therefore, patients with KIT-negative GISTs should not, a priori, be denied imatinib therapy... - Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinasesMichael C Heinrich
Department of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, Oregon 97239 3098, USA
Clin Cancer Res 14:2717-25. 2008..To evaluate the activity of imatinib in treating advanced, life-threatening malignancies expressing one or more imatinib-sensitive tyrosine kinases... 
Determination of stromal signatures in breast carcinomaRobert B West
Department of Pathology, Stanford University Medical Center, Stanford, California, USA
PLoS Biol 3:e187. 2005..Our findings suggest that the host stromal response varies significantly among carcinomas and that gene expression patterns characteristic of soft tissue tumors can be used to discover new markers for normal connective tissue cells...- Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)Michael C Heinrich
Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR, USA
J Clin Oncol 24:1195-203. 2006..To determine the clinical efficacy of imatinib in patients with advanced aggressive fibromatosis (AF) and to identify the molecular basis of response/nonresponse to this agent... - Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GrMichael C Heinrich
Division of Hematology Oncology, Department of Medicine and Cell and Developmental Biology, Portland Veterans Affairs Medical Center and Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
J Clin Oncol 26:5360-7. 2008..In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing... - Primary extragastrointestinal stromal tumor of the pleura: report of a unique case with genetic confirmationKevin B Long
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Am J Surg Pathol 34:907-12. 2010..This seems to be the first EGIST arising above the diaphragm. This case shows a potential diagnostic pitfall with therapeutic consequences... - KIT mutations are common in testicular seminomasKathleen Kemmer
Division of Hematology and Oncology, Oregon Health and Science University Cancer Institute and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
Am J Pathol 164:305-13. 2004..These findings suggest that activating KIT mutations may contribute to tumorigenesis in a subset of seminomas, but are not involved in NSGCT... - Immunohistochemical and molecular markers in breast phyllodes tumorsVeselina B Korcheva
Department of Pathology, L471, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
Appl Immunohistochem Mol Morphol 19:119-25. 2011..The significance of the FBX4 substitution deserves further investigation... - Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progressionBernadette Liegl
Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Am J Surg Pathol 33:218-26. 2009..The rhabdomyoblastic differentiation can represent a diagnostic pitfall. The molecular mechanisms for this form of TKI-resistant clonal evolution remain to be determined... - KIT gene mutations and copy number in melanoma subtypesCarol Beadling
Oregon Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
Clin Cancer Res 14:6821-8. 2008..To determine the frequency of KIT mutations across melanoma subtypes, we surveyed a large series of tumors... - Biology of gastrointestinal stromal tumorsChristopher L Corless
Oregon Health and Science University Cancer Institute, Department of Pathology, Portland, OR, USA
J Clin Oncol 22:3813-25. 2004..In addition, the role of mutation screening in KIT and PDGFRA as a diagnostic and prognostic aid is emphasized in this review... - BRAF in papillary thyroid carcinoma of ovary (struma ovarii)Jason Schmidt
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Am J Surg Pathol 31:1337-43. 2007..In this study, we explored the possible role of these genes in the development of BSO and MSO... - Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinomaShi Long Lu
Department of Otolaryngology, OHSU Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
Genes Dev 20:1331-42. 2006..Our data suggest that targeting common oncogenic pathways in tumor epithelia together with blocking the effect of TGFbeta1 on tumor stroma may provide a novel therapeutic strategy for HNSCC... - A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumorsInigo Espinosa
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
Am J Surg Pathol 32:210-8. 2008..5%) synovial sarcomas among the 935 soft tissue tumors examined showed positive immunostaining for DOG1.1. In addition, DOG1.1 immunoreactivity was seen in fewer cases of carcinoma, melanoma, and seminoma as compared with KIT... - Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesionsMegan L Troxell
Department of Pathology and Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
Mod Pathol 25:930-7. 2012..These findings raise interesting questions about the role of PIK3CA/AKT pathway in breast carcinogenesis, and the biologic/precursor potential of columnar cell lesions... - "Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behaviorTanya A Rege
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Am J Surg Pathol 35:495-504. 2011..Recognition of "pediatric-type" GISTs in adults is critical for prognosis, appropriate therapy, and follow-up... - Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinomaJennifer Dunlap
Department of Pathology, Oregon Health and Science University, L471, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA
Breast Cancer Res Treat 120:409-18. 2010.... - Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapyMichael C Heinrich
OHSU Cancer Institute, Oregon Health and Science University and VA Medical Center, Portland, Oregon 97239, USA
J Surg Oncol 90:195-207; discussion 207. 2005..The importance of a multi-disciplinary approach using both surgery and imatinib therapy is emphasized... - PDGFRA activating mutations in gastrointestinal stromal tumorsMichael C Heinrich
Department of Medicine, Department of Pathology, Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR 97201, USA
Science 299:708-10. 2003..Thus, KIT and PDGFRA mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs... - Mucinous breast carcinomas lack PIK3CA and AKT1 mutationsElizabeth L Kehr
Department of Pathology, Oregon Health and Science University, Portland, OR 97239, USA
Hum Pathol 43:2207-12. 2012..This series represents the largest study, to date, of PIK3CA genotyping in mucinous carcinoma and supports the unique pathogenetics of invasive mucinous breast carcinoma... - Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registryCarol Beadling
Division of Hematology Oncology, Oregon Health and Science University, Portland, Oregon, USA
J Mol Diagn 13:504-13. 2011..These findings demonstrate the diversity and complexity of mutations in druggable targets among the different cancer types and underscore the need for a broad-spectrum, prospective genotyping approach to personalized cancer medicine... - Absence of BRAF and NRAS mutations in uveal melanomaFrank Cruz
Oregon Health and Science University OHSU Cancer Institute, Department of Pathology, OHSU and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
Cancer Res 63:5761-6. 2003..No NRAS exon 1 mutations were detected in either type of melanoma. We conclude that UMs arise independent of oncogenic BRAF and NRAS mutations, an observation that may have implications for therapies targeted to the NRAS-BRAF pathway... - Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomasMichael C Heinrich
Department of Medicine, Oregon Health Science University Cancer Institute, Portland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR 97201, USA
Cancer Treat Res 120:129-50. 2004 - Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignanciesMichael C Heinrich
Department of Medicine, Division of Hematology Oncology, Oregon Health and Science University, USA
J Clin Oncol 20:1692-703. 2002..In this review, we discuss the rationale for and development of KIT tyrosine kinase inhibitors for the treatment of human malignancies... - BRAF and KRAS mutations in sporadic glomus tumorsAndrea Chakrapani
Department of Pathology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
Am J Dermatopathol 34:533-5. 2012..A KRAS G12A mutation was found in tumor removed from the finger. Ki-67 index did not correlate with genotype. To our knowledge, this is the first report of oncogenic mutations in sporadic glomus tumors... - Gastrointestinal stromal tumours: origin and molecular oncologyChristopher L Corless
Knight Cancer Institute, Division of Haematology and Oncology, and Department of Pathology, Portland VA Medical Center and Oregon Health and Science University, Portland, OR 97239, USA
Nat Rev Cancer 11:865-78. 2011..Further improvements in GIST treatment may require targeting GIST stem cell populations and/or additional genomic events... - The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation statusRobert B West
Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
Am J Pathol 165:107-13. 2004..Reactivity for DOG1 may aid in the diagnosis of GISTs, including PDGFRA mutants that fail to express KIT antigen, and lead to appropriate treatment with imatinib mesylate, an inhibitor of the KIT tyrosine kinase... - Multiplex high-throughput gene mutation analysis in acute myeloid leukemiaJennifer Dunlap
Department of Pathology, Oregon Health and Science University, Portland, OR 97239, USA
Hum Pathol 43:2167-76. 2012..This approach will be helpful in defining prognostic subgroups of acute myeloid leukemia and contribute to the selection of patients for enrollment into trials with novel inhibitors... - KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in sizeChristopher L Corless
Department of Pathology, Division of Hematology Oncology, Oregon Health and Science University, Portland, 97201, USA
Am J Pathol 160:1567-72. 2002..The findings suggest that KIT mutations per se are of little prognostic importance in GISTs... - Resistance of prostate cancer cell lines to COX-2 inhibitor treatmentMatthew Wagner
Division of Urology and Renal Transplantation, Oregon Health and Science University, Oregon Cancer Institute, Portland, OR, USA
Biochem Biophys Res Commun 332:800-7. 2005..In conclusion, these studies indicate the lack of a putative role for COX-2 in prostate cancer development. Direct evidence for the involvement of COX-2 in prostate cancer carcinogenesis is desperately needed... - Hepatic and cardiac iron overload among patients with end-stage liver disease referred for liver transplantationAvital Y O'Glasser
Division of Gastroenterology and Hepatology, Department of Medicine, Oregon Health and Science University and the Portland Veterans Affairs Medical Center, Portland, OR 97219, USA
Clin Transplant 24:643-51. 2010..Myocardial iron deposits were observed post-mortem in patients who died of cardiac events after transplantation at our institution. This observation prompted testing to exclude cardiac iron in subsequent transplant candidates... - Outcome following surgical therapy for gastrointestinal stromal tumorsManeesh Gupta
Department of Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
J Gastrointest Surg 10:1099-105. 2006..Mitotic index and the presence of metastases remain the primary predictors of postoperative survival. Complete surgical resection, even if multivisceral resection is required, is associated with improved survival... - A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cellsRobert B West
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
Proc Natl Acad Sci U S A 103:690-5. 2006.... - Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasiaTerry K Morgan
Department of Pathology, Oregon Health and Science University, Portland, Oregon 97239, USA
Cancer Cytopathol 121:37-46. 2013..The data from the current study indicate that a novel monoclonal antibody, HPC2 1-B3, may facilitate the diagnosis of early pancreatic dysplasia... - Biphasic Papillary and Lobular Breast Carcinoma With PIK3CA and IDH1 MutationsDaphne Ang
Department of Pathology Knight Cancer Institute, Oregon Health and Science University, Portland, OR Department of Pathology, Stanford University, Stanford, CA
Diagn Mol Pathol 21:221-4. 2012..The characterization of activating point mutations in morphologic special types of breast carcinoma may suggest avenues amenable to targeted therapy... - Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancerEugene Y Chang
Department of Surgery, Oregon Health and Science University, Mail Code L223A, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
Am J Surg 193:614-7; discussion 617. 2007..We hypothesized that routine pathologic examination fails to identify some residual cancer... - Percutaneous bioprosthetic venous valve: a long-term study in sheepDusan Pavcnik
Dotter Interventional Institute, Oregon Health Sciences University and Portland Veterans Administration Medical Center, 97201, USA
J Vasc Surg 35:598-602. 2002..Slight to moderate leaflet thickening was found mostly at their bases. Percutaneously placed SIS BVV is a promising one-way, competent valve that resists venous back-pressure while allowing forward flow... - Experimental percutaneous extrahepatic portacaval shunt creation by transjugular approach in SwineChang Kyu Seong
Dotter Interventional Institute, Oregon Health and Science University, L342, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA
Cardiovasc Intervent Radiol 28:616-23. 2005..None of the tested rigid stent-grafts were suitable for PEPS creation. A short flexible stent-graft with flanged ends is suggested for further exploration... - Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplantsSusan L Orloff
Portland Veterans Affairs Medical Center, Portland, Oregon 97201, USA
Transplantation 73:679-88. 2002..This study examined the role of CMV and the alloreactive response in the development of TVS using bone marrow chimerism (BMC) in rat small bowel (SB) and heart transplantation models... - Immunosuppression impact on long-term cardiovascular complications after liver transplantationJohn M Rabkin
Department of Surgery, Division of Abdominal Organ Transplantation, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd L590, Portland, Oregon 97201 3098, USA
Am J Surg 183:595-9. 2002..Cardiovascular disease and associated risk factors have been shown in renal transplant patients to be related to the pharmacologic immunosuppression employed... - Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotypingCarol Beadling
Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon
J Mol Diagn 15:171-6. 2013..The rapid turnaround time and low input DNA requirements make the multiplex PCR and semiconductor-based sequencing approach a viable option for mutation detection in a clinical laboratory... - The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinomaJody E Hooper
Department of Pathology, Oregon Health and Science University, Portland, OR 97239, USA
Hum Pathol 43:1583-9. 2012..01). The combination of both markers provided even better specificity and positive likelihood ratios. We conclude that HPC2 and N-cadherin significantly improve accurate classification of pancreatic cancer and cholangiocarcinoma... - Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation studyLeona A Doyle
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA Department of Pathology and Knight Cancer Institute, Oregon Health and Science University Division of Hematology and Medical Oncology, Portland VA Medical Center and Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
Histopathology 61:801-9. 2012..Immunohistochemistry for SDHB can be used to confirm the diagnosis of this tumour class. SDHB expression is retained in all GISTs with KIT and PDGFRA mutations... - In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumorsGayathri R Devi
AVI BioPharma, Inc, Corvallis, Oregon and Oregon Health and Science University Cancer Institute, Portland, Oregon, USA
Clin Cancer Res 11:3930-8. 2005..Data from both human studies indicated similar plasma concentration-time profile. These studies show PMO bioavailability in tumor tissue and establish the feasibility of using PMO targeting specific genes in human cancer clinical trials... - Percutaneous vein occlusion with small intestinal submucosa: an experimental pilot study in Swine and sheepMan Deuk Kim
Dotter Interventional Institute, Oregon Health and Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
Cardiovasc Intervent Radiol 30:725-30. 2007..Our hypothesis was that SIS would cause vein occlusion... - State-of-the art therapy for gastrointestinal stromal tumorsCharles D Blanke
Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97201, USA
Cancer Invest 23:274-80. 2005..Questions remain about the optimal dose of imatinib, whether to continue drug in the setting of progressive disease, and how best to prevent or overcome resistance... - Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplantsDaniel N Streblow
Departments of Molecular Microbiology, Oregon Health Sciences University, Portland, Oregon 97201, USA
J Virol 77:2182-94. 2003..These results suggest that CMV-induced acceleration of TVS involves the increased graft vascular infiltration of inflammatory cells through enhanced chemokine expression... - A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancerJacob Schwartzman
Division of Hematology Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
Epigenetics 6:1248-56. 2011..These results demonstrate that bead arrays offer a high-throughput method to discover novel genes with promoter DNA methylation such as ERG, whose measurement may improve our ability to more accurately detect prostate cancer... - Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomyTomasz M Beer
Division of Hematology and Medical Oncology, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, CR 145, Portland, OR 97239, USA
Cancer Epidemiol Biomarkers Prev 13:2225-32. 2004..In this study, we selected this approach to test several hypotheses about the effect of calcitriol (1,25-dihydroxycholecalciferol), the active form of vitamin D, on early-stage human prostate cancer... - Sentinel node staging of primary melanoma by the "10% rule": pathology and clinical outcomesRachel E Emery
School of Medicine, L109 Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
Am J Surg 193:618-22; discussion 622. 2007..Although some suggest removal of only the "hottest" SLN, the "10% rule" dictates that nodes are removed until the background count is 10% or less of the count of the "hottest" node... - Protein kinase A RII-like (R2D2) proteins exhibit differential localization and AKAP interactionAmy E Hanlon Newell
VA Medical Center and Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA
Cell Motil Cytoskeleton 65:539-52. 2008..Based on location, affinity for AKAPs and lack of affinity for cAMP, it appears that each R2D2 protein has a unique role in this process... - The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomasVassil Kaimaktchiev
OHSU Cancer Institute and Department of Pathology, Oregon Health and Science University, Portland, OR 97239, USA
Mod Pathol 17:1392-9. 2004..CDX2 may also be helpful in distinguishing adenocarcinomas of the ampulla from those arising in the pancreas and biliary tree... - Effects of blood flow and/or ventilation restriction on radiofrequency coagulation size in the lung: an experimental study in swineHiroshi Anai
Dotter Interventional Institute, Oregon Health and Science University, Portland, Oregon 97201-3098, USA
Cardiovasc Intervent Radiol 29:838-45. 2006..The value of these restrictions for potential clinical use needs to be explored in experimentally induced lung tumors... - Distinctive morphology of renal cell carcinomas in tuberous sclerosisAndrew Schreiner
Department of Pathology, Division of Urology and Renal Transplantation, Oregon Health and Science University, Portland, OR 97239, USA
Int J Surg Pathol 18:409-18. 2010..The histopathological features of these carcinomas illustrate characteristics of renal carcinoma that are probably related to genetic alterations of tuberous sclerosis... - Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferationShi Long Lu
Department of Otolaryngology, Oregon Health and Science University, Portland, USA
Cancer Res 64:4405-10. 2004..These phenotypes correlated with enhanced Smad signaling in transgenic epithelia and stroma. Our study suggests that TGF-beta1 overexpression at early stages of HNSCC formation provides a tumor promoting microenvironment... - Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patientsAtif Zaman
Division of Gastroenterology and Hepatology, Oregon Health and Science University, Portland, Oregon 97201, USA
Am J Med 120:280.e9-14. 2007..Our objective was to prospectively validate a panel of serum fibrosis markers (FIBROSpect(SM) II) that has been recently developed... - The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylaseVladimir Vartanian
Center for Research on Occupational and Environmental Toxicology and Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR 97239 3098, USA
Proc Natl Acad Sci U S A 103:1864-9. 2006..These data suggest an important role for NEIL1 in the prevention of the diseases associated with the metabolic syndrome... - The value of traditional upper endoscopy as a diagnostic test for Barrett's esophagusAmy Wang
Department of Gastroenterology, Oregon Health and Science University, Portland, Oregon 97239, USA
Gastrointest Endosc 68:859-66. 2008..The standard test for diagnosing Barrett's esophagus (BE) is a conventional upper endoscopy. However, studies have shown that confirmation of BE by endoscopy with histologic intestinal metaplasia can be difficult... - High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failureJason D Estes
Division of Liver Pancreas Transplantation, Oregon Health and Science University, Portland, OR 97201, USA
Arch Surg 138:852-8. 2003..The use of potentially hepatotoxic herbal and dietary supplements is highly prevalent in the fulminant hepatic failure (FHF) patient population at our institution, and this subgroup of patients has a worse prognosis... - Graft failure from severe recurrent primary sclerosing cholangitis following orthotopic liver transplantationDeepak V Gopal
Division of Gastroenterology and Hepatology, Oregon Health Sciences University and Portland VA Medical Center, Portland, Oregon 97207, USA
J Clin Gastroenterol 37:344-7. 2003..CONCLUSIONS: Although most series report mild recurrence of PSC following OLT, this case illustrates that early, severe recurrence of PSC may occur, leading to graft failure and need for re-transplantation... - Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134)John K Petty
Department of Surgery, Section of Surgical Oncology, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, L223A, Portland, OR 97201-3098, USA
Am J Surg 183:512-8. 2002..This correlation with survival and our previous preclinical research suggest a basis for an OX-40 immunotherapy trial... - Transplanted human bone marrow contributes to vascular endotheliumShuguang Jiang
Center for Hematologic Malignancies, Division of Hematology and Medical Oncology, Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
Proc Natl Acad Sci U S A 101:16891-6. 2004..Transplantable bone marrow-derived endothelial progenitor cells may represent novel therapeutic targets for hematopoietic and vascular disease... - KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized?Jonathan A Fletcher
Am J Pathol 161:737-8; author reply 738-9. 2002 - NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelinesGeorge D Demetri
J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007.... - Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridizationAbbas Agaimy
Institute of Pathology, Klinikum Nürnberg, 90419 Nurnberg, Germany
Oncol Rep 18:9-15. 2007.... - Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection after liver transplantation: a case control analysis of 210 donor-recipient pairsSaad F Jazrawi
Liver Transplantation Program, the Division of Gastroenterology Hepatology, Portland Veterans Administration Medical Center, OR 97207, USA
Liver Transpl 9:377-82. 2003..In this large case control analysis of patients undergoing liver transplantation for diverse etiologies, TNF promoter polymorphisms were not independently associated with rejection or survival... - Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KITSebastian Bauer
Department of Internal Medicine Cancer Research, University of Essen Medical School, Germany
Cancer Chemother Pharmacol 51:261-5. 2003..Our experience with this patient suggests that even GISTs with very low levels of KIT expression may respond to imatinib mesylate therapy... - Gastrointestinal stromal tumourBrian P Rubin
Department of Anatomic Pathology, Taussig Cancer Center and the Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Lancet 369:1731-41. 2007..The important interplay between the molecular genetics of gastrontestinal stromal tumour and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumours... - Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic featuresCiarán O'Riain
Department of Histopathology, St Vincent s University Hospital, Elm Park, Dublin, Ireland
Am J Surg Pathol 29:1680-3. 2005..Two smaller lesions from this patient were heterozygous for the mutation. This phenomenon has been observed in up to 8% of sporadic malignant GISTs but has not been documented in familial disease... - Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1Douglas R Stewart
J Med Genet 44:e61. 2007..We hypothesise that the LOH of NF1 and lack of KIT and PDGFRA mutations are evidence of an alternative pathogenesis in NF1-associated GISTs... - Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutationJanet Graham
Beatson Oncology Centre, Glasgow, United Kingdom
Arch Pathol Lab Med 131:1393-6. 2007..To our knowledge, this is only the second germline example of this particular mutation. The patient's esophageal tumors were stabilized with imatinib... - Major response to imatinib mesylate in KIT-mutated melanomaF Stephen Hodi
The Melanoma Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
J Clin Oncol 26:2046-51. 2008 - Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KITLawrence H Einhorn
Department of Medicine, Division of Hematology Oncology, Indiana University, Indianapolis, Indiana and Walther Cancer Institute, Indianapolis, IN, USA
Am J Clin Oncol 29:12-3. 2006..This phase II study was conducted to determine the activity of imatinib (gleevec) in heavily pretreated patients with KIT-positive metastatic germ cell tumor... - Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225Grant A McArthur
Peter MacCallum Cancer Centre, East Melbourne, Australia
J Clin Oncol 23:866-73. 2005..The purpose of this study was to evaluate molecular, cytogenetic, and kinase activation profiles in a series of DFSPs and to determine whether these biologic parameters are correlated with the clinical responses of DFSP to imatinib... - Comparison of the endothelialization of small intestinal submucosa, dacron, and expanded polytetrafluoroethylene suspended in the thoracoabdominal aorta in sheepKivilcim Yavuz
Department of Radiology, Royal Perth Hospital, Perth, Australia
J Vasc Interv Radiol 17:873-82. 2006..Further study of its durability and incorporation into the aortic wall needs to be performed to evaluate its suitability as a cover for aortic endografts... - Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumorsKatherine A Janeway
Department of Medicine, Children s Hospital Boston, MA, USA
Cancer Res 67:9084-8. 2007..KIT activation levels in pediatric KIT-wild-type GISTs are comparable with those in KIT-mutant GISTs. Therapies that inhibit KIT activation, or crucial KIT signaling intermediates, should be explored in pediatric KIT-wild-type GIST... - Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 casesJerzy Lasota
Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
Mod Pathol 21:476-84. 2008..The latter is also true for all KIT exon 17 mutant GISTs... - Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumorsJayesh Desai
Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 13:5398-405. 2007..The objective of this study was to correlate molecular and radiologic patterns of imitinib-refractory disease with existing conventional criteria for disease progression... - Assessing the prognosis of gastrointestinal stromal tumors: a growing role for molecular testingChristopher L Corless
Am J Clin Pathol 122:11-3. 2004 - Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the "hepatitis C 3" multi-institutional trial experienceGeorge J Netto
Departments of Pathology, Baylor University Medical Center, Dallas, Tex, USA
Arch Pathol Lab Med 130:1157-62. 2006..Establishing adequate interobserver agreement is crucial not only for standardization of patient care but also to ensure validity of findings in multi-institutional trials... - Angiotensin II type 1 and 2 receptors in conduit arteries of normal developing microswineSusan P Bagby
Department of Medicine, Oregon Health and Science University and Portland VA Medical Center, USA
Arterioscler Thromb Vasc Biol 22:1113-21. 2002.... - TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studiesJefferson Terry
Genetic Pathology Evaluation Centre, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
Am J Surg Pathol 31:240-6. 2007..Our findings establish TLE as a robust immunohistochemical marker for synovial sarcoma, and may have implications for understanding the biology of synovial sarcoma and for developing experimental therapies for this cancer... - Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomachRobert J Coffey
Department of Medicine, Vanderbilt University Medical Center and Nashville Veterans Affairs Medical Center, Nashville, Tennessee, USA
J Clin Invest 117:70-80. 2007.... - Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinomaShomik Sengupta
Department of Urology, Mayo Clinic, Rochester, Minnesota, USA
J Urol 175:53-6. 2006..These findings indicate that imatinib therapy is unlikely to be effective in patients with high grade RCC...